Fig. 2.

Seronegative patients who received vaccination prior to transplantation are primed to mount faster and more robust anti-gB antibody responses once challenged with the virus in comparison to delayed responses in placebo recipients.

Total anti-gB antibody levels were measured by standard ELISA and are shown as follows: A) for individual vaccinees (n = 10) and B) placebo (n = 4) recipients; C-D) The average anti-gB antibody responses are presented for vaccine (C) placebo patients (D): Serum samples were collected at the time of vaccination (baseline, dotted line), time of transplantation and on days: 7, 35, 63 and 90 post-transplant. Where an individual point (in A & B) is missing a sample was not available for that timepoint for analysis. Combined sera from healthy seropositive donors (n = 6) was used as a positive control. Dashed line represents the cut off and was informed by control sera taken from healthy seronegative individuals (n = 6).